Last updated: 02/27/2026 12:30:18

A study assessing the safety, efficacy, and impact of GlaxoSmithKline Biologicals' RTS, S/AS01E malaria vaccine in young children across sub-Saharan AfricaEPI-MAL-003

GSK study ID
115056
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/AS01E vaccine in young children in sub-Saharan Africa
Trial description: The RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced. Along with safety, researchers will also assess how well the vaccine works and its overall impact on children's health.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Incidence rates of adverse events of special interest (AESI)

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of aetiology-confirmed meningitis

Timeframe: During the entire study period (From Day 0 up to Month 62)

Secondary outcomes:

Incidence rate of probable meningitis (final classification)

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of clinically suspected meningitis (final classification)

Timeframe: During the entire study period (From Day 0 up to Month 62)

Number of meningitis cases identified at site level (first line laboratory)

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of cerebral malaria (diagnosed by Rapid Diagnostic Test [RDT] and/or microscopy)

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of malaria episodes diagnosed by RDT and/or microscopy

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of anaemia cases at hospital entry among hospitalised children

Timeframe: During the entire study period (From Day 0 up to Month 62)

Incidence rates of hospitalisation cases

Timeframe: During the entire study period (From Day 0 up to month 62)

Number of deaths

Timeframe: During the entire study period (From Day 0 up to month 62)

Interventions:
Procedure/surgery: Whole blood sample
Enrollment:
77953
Observational study model:
Cohort
Primary completion date:
2025-07-08
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Malaria
Product
SB257049
Collaborators
Not applicable
Study date(s)
March 2019 to August 2025
Type
Observational
Phase
4

Participation criteria

Sex
Female & Male
Age
Not applicable - 5 Years
Accepts healthy volunteers
Yes
  • Inclusion Criteria
  • All study participants must satisfy ALL the following criteria at study entry:

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Navrongo, Ghana, N/A
Status
Study Complete
Location
GSK Investigational Site
Mangochi, Malawi, N/A
Status
Study Complete
Location
GSK Investigational Site
Kintampo, Ghana, N/A
Status
Study Complete
Location
GSK Investigational Site
Chikwawa, Malawi, N/A
Status
Study Complete
Location
GSK Investigational Site
Kisumu, Kenya, 4 0100
Status
Study Complete

Study documents

No study documents available.

Results overview

No study documents available

Recruitment status
Finalized
Actual primary completion date
2025-07-08
Actual study completion date
2025-07-08

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website